Register

Nephrology

Hematology   

Questions discussed in this category

For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
What are your management strategies for patients with chronic kidney disease attributed to deferasirox use who require frequent blood products for a hematologic disorder?
1 Answer available
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
2 Answers available
How do you dose apixaban in patients with CrCl <30 mL/minute?
1 Answer available
What are the factors that you would consider for the use of ESA in patients with anemia of CKD with a history of stroke or TIA?
1 Answer available
Do you consider starting hydroxyurea in a patient with hemoglobin S-beta thalassemia with chronic kidney disease secondary to FSGS?
No transfusion dependence but has hemoglobin in the 8-9 g/dl range.
1 Answer available
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
If there are light chain deposits on the kidney, is that conclusive of MGRS?
1 Answer available
Would you recommend complement testing in a kidney transplant recipient with chronic antibody-mediated rejection and biopsy-proven thrombotic microangiopathy to determine the need for eculizumab?
1 Answer available
Would you recommend oral or intravenous iron in a chronic kidney disease stage 4 patient who is not on an ESA and has a hemoglobin of 12.7 g/dl and an iron saturation of less than 20%?
3 Answers available
How do you manage recurrent hemodialysis filter clotting in an in-center ESKD patient with heparin-induced thrombocytopenia?
1 Answer available
Would you recommend use of ESA for anemia of kidney disease in the setting of metastatic solid tumor malignancy?
1 Answer available
Do you recommend starting aspirin for a patient with ESKD secondary to lupus nephritis with detected antiphospholipid antibodies on pretransplant workup but no history of a thrombotic event?
3 Answers available
Have you encountered acute kidney injury after starting eltrombopag for aplastic anemia as part of triple immunosuppressive regimen with ATG and cyclosporine?
1 Answer available
How do you manage anticoagulation bridging for outpatient ESKD patients given concerns for bleeding risk with enoxaparin in this population?
Would you bridge with enoxaparin 0.7 mg/kg/day in an ESKD patient, as described in a previous retrospective study (Pon et al., PMID: 24718051)?
1 Answer available
Would you consider clearing a patient with essential thrombocytosis for a kidney donation?
1 Answer available
Do you hold IV iron in the setting of active infection?
1 Answer available
How would you manage an incidental catheter-related thrombosis in a functioning dialysis catheter?
- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...
2 Answers available
What is your preferred first line regimen for myeloma with severe renal impairment, either on or off dialysis?
1 Answer available
Is there any role for iron chelation in a patient with iatrogenic transfusion-induced iron overload such as in patients with end-stage kidney or liver disease?
Does transplant eligibility make a difference for management?
1 Answer available
Would you consider giving ESA for anemia secondary to chronic kidney disease in a patient with follicular lymphoma in remission and on rituximab maintenance?
1 Answer available


Papers discussed in this category

PLoS One, 2021 Apr 08
Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study.
Am J Kidney Dis, 2019 Aug 05
The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Circulation, 2022 Nov 06
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Circulation, 2022 Nov 06
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
J Rheumatol, 2017 May 15
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Circulation, 2011-12-20
What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013-01
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
American journal of nephrology, 2013
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
Journal of the American Heart Association, 2021 Jun 26
Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan.

Related Topics in Nephrology

Copyright © 2024 theMednet
All Rights Reserved.